NAD+ sirtuins, DNA repair, and strategies to restore its levels
Nicotinamide adenine dinucleotide (NAD+) is central to hundreds of metabolic reactions. Its cellular levels decline by approximately 50% between the ages of 20 and 60, correlating with mitochondrial decline, loss of DNA repair capacity, and sirtuin depletion. Understanding the biochemistry of NAD+ is essential for evaluating restoration strategies: NMN, NR, and direct injections.
NAD+: the central molecule of energy metabolism
What is NAD+?
NAD+ (nicotinamide adenine dinucleotide, oxidized form) is a coenzyme present in all living cells. It plays a structuring role in two major categories of biological processes:
- Redox reactions NAD+ accepts electrons to form NADH, which serves as an electron carrier in glycolysis, the Krebs cycle, and the mitochondrial respiratory chain. Without NAD+, ATP production by mitochondria collapses.
- Cellular signaling NAD+ is a substrate consumed (not recycled) by signaling enzymes: sirtuins (SIRT1-7), PARP-1 (DNA repair), and CD38/CD157 (calcium signaling).
This second role explains why maintaining high levels of NAD+ is crucial: each activation of PARP-1 during a DNA break, each cycle of sirtuin consumes and degrades NAD+ into nicotinamide (NAM) or ADP-ribose.
Formula: C₂₁H₂₇N₇O₁₄P₂⁻. Molecular weight: 663.4 Da. The total pool of NAD+ in a human muscle cell is approximately 0.2–0.5 nmol/mg of protein. NAD+ does not cross cell membranes freely: oral supplementation requires precursors (NMN, NR, Nam) that enter the cell and are then converted to NAD+.
The decline of NAD+ with age
Studies of human muscle and liver biopsies show a 40 to 60% reduction in NAD+ levels between the ages of 20 and 60. This decline is multifactorial:
CD38 is a NADase whose activity increases with chronic low-grade inflammation (inflammaging). CD38 degrades NAD+ into cyclic ADP-ribose and NAM. CD38-KO mice maintain high NAD+ levels well into old age.
The accumulation of DNA damage with age → prolonged activation of PARP-1 (DNA repair enzyme) → increased consumption of NAD+. This cycle creates a progressive depletion of the NAD+ pool.
NAMPT (nicotinamide phosphoribosyltransferase) is the rate-limiting enzyme in the NAM → NMN → NAD+ rescue pathway. Its expression decreases in aged tissues, reducing the endogenous synthesis capacity of NAD+.
Sirtuines: the "guardians of the genome" dependent on NAD+
Sirtuins (SIRT1 to SIRT7) are NAD+-dependent deacetylases that regulate a considerable proportion of the genome via post-translational modifications of histones and non-histone proteins. Their activity is directly proportional to intracellular NAD+ levels.
| Sirtuine | Location | Main functions | Link to aging |
|---|---|---|---|
| SIRT1 | Nucleus / cytoplasm | p53 deacetylation, NF-κB, PGC-1α; metabolism, inflammation | ↓ with age; ↑ with calorie restriction |
| SIRT3 | Mitochondria | Regulation of the respiratory chain, SOD2, Krebs cycle | Protects against age-related metabolic diseases |
| SIRT6 | Core | DNA repair (BER, NHEJ), telomeric stability, carbohydrate metabolism | Sirt6-KO mice age prematurely |
| SIRT1/SIRT6 | Core | Regulation of PGC-1α → mitochondrial biogenesis | Correlated with aerobic capacity in centenarians |
The NAD+→SIRT1→PGC-1α axis is particularly studied for its role in mitochondrial biogenesis: in the presence of high NAD+, SIRT1 deacetylates and activates PGC-1α, the master regulator of mitochondrial biogenesis. This cascade directly links NAD+ levels to the quality and number of functional mitochondria.
PARP-1 and DNA repair
PARP-1 (poly-ADP-ribose polymerase 1) is the first-response enzyme to single- and double-strand breaks in DNA. Upon activation, a single molecule of PARP-1 can consume tens to hundreds of NAD+ molecules in a matter of minutes. Paradoxically:
- High levels of NAD+ allow PARP-1 to rapidly repair damage → genomic protection
- Chronic PARP-1 hyperactivation (due to age-related damage) depletes the NAD+ pool → deleterious effect
- PARP inhibitors have been used in oncology precisely to exploit this mechanism in cancer cells deficient in homologous repair
Sufficient levels of NAD+ → functional PARP-1 → rapid repair of DNA breaks → less persistent damage → less inflammatory activation → less CD38 activation → maintenance of the NAD+ pool. Restoring NAD+ could therefore interrupt a harmful cycle of aging.
Biosynthetic pathways and precursors
Cells synthesize NAD+ via three main pathways, which determines which precursors are most effective for supplementation:
| Precursor | Way | Conversion to NAD+ | Oral bioavailability | Human data |
|---|---|---|---|---|
| NAD+ IV/IM direct | N/A (direct) | Limited intracellular conversion (extracellular degradation) | N / A | Pilot studies, tolerance confirmed |
| NMN (Nicotinamide Mononucleotide) | Emergency lane (direct) | NMN → NAD+ via NMNAT | Moderate; varies depending on age and tissue | Several positive RCTs phase 1-2 |
| NR (Nicotinamide Riboside) | (Indirect) escape route | NR → NMN → NAD+ via NRK1/2 | Good; absorbed intact in the intestine | Multiple RCTs; elevated blood NAD+ confirmed |
| Name (Nicotinamide) | (Indirect) escape route | Nam → NMN via NAMPT | Excellent but dose-limiting (saturated NAMPT) | Old, well-documented |
| NA (Nicotinic Acid, Niacin) | Preiss-Handler Lane | NA → NAMN → NAAD → NAD+ | Excellent but vasomotor flushing | History (cholesterol) |
| Trp (Tryptophan) | De novo route (kynurenine) | Long, ineffective (60 mol Trp → 1 mol NAD+) | Variable | Marginal contribution to adulthood |
NMN vs NR: what is the concrete difference?
NMN (Nicotinamide Mononucleotide)
NMN is the immediate precursor of NAD+ in the rescue pathway. It must first enter cells (via the Slc12a8 transporter described in mice, or by extracellular dephosphorylation at NR) before being converted to NAD+ by NMNATs (nicotinamide mononucleotide adenylyltransferases). Human studies show a significant increase in NAD+ in whole blood, muscle, and potentially other tissues after NMN supplementation (250–1000 mg/day).
NR (Nicotinamide Riboside)
NR is a form of vitamin B3 absorbed intact in the intestine via specific transporters (SLC29A1/2). It is then phosphorylated to NMN by NRK1/2 kinases. NR is the best-documented form in terms of raising blood NAD+ levels in humans, with numerous randomized studies confirming its efficacy in increasing NAD+ levels by 40 to 100%, depending on the dose and tissue.
- Direct precursor: NMN → NAD+
- Carrier-dependent absorption Slc12a8
- Growing human studies (2020–2024)
- Effective dose: 250–500 mg/day
- Subcutaneous injections studied
- Indirect precursor: NR → NMN → NAD+
- Documented intact intestinal absorption
- The most studied in humans (>15 RCTs)
- Effective dose: 300–1000 mg/day
- Preferred oral form in clinical research
NAD+ injections: pharmacokinetics and benefits
Parenteral administration of NAD+ (IV or subcutaneous) bypasses the limitations of oral bioavailability. However, exogenous NAD+ does not directly cross cell membranes—it must first be hydrolyzed to NMN or AMP-ribose outside the cell, and then the resulting precursors enter intracellular biosynthetic pathways. Extracellular enzymes (CD73, CD38) participate in this process.
Despite theoretical limitations in direct cellular bioavailability, high-dose IV infusions of NAD+ (0.5–2 g) are used in anti-aging clinics and in addiction treatment (alcohol withdrawal, dependencies). The hypothesis is that rapid extracellular conversion to NMN/NR generates a sufficiently high peak of available precursors to saturate cellular entry transporters and significantly increase the intracellular pool of NAD+.
Key clinical studies
| Study | Compound | N / Duration | Main result |
|---|---|---|---|
| Yoshino et al. 2021 Science |
NMN 250 mg/day orally | 25 menopausal women, 10 weeks | ↑ NAD+ muscle +% , ↑ insulin sensitivity muscle (+25% Akt signaling) |
| Dollerup et al. 2020 Cell Rep Med |
NR 1000 mg/day oral | 40 obese men, 12 weeks. | Increased NAD+ metabolites in blood, no effect on overall insulin sensitivity |
| Martens et al. 2020 Nat Commun |
NR 1000 mg/day oral | 24 healthy elderly adults, 21 days | ↑ Blood NAD+ +60%, ↓ Systolic blood pressure −5 mmHg, ↓ Inflammatory markers |
| Remie et al. 2020 Nat Commun |
NR 1000 mg/day oral | 13 obese men, 6 weeks old. | Increased NAD+ in liver and muscle (¹H-NMR spectroscopy), improved liver lipids |
| Pencina et al. 2023 J Clin Endocrinol Metab |
NMN 600 mg/day orally | 32 men aged 12 weeks. | Increased NAD+ in blood, increased walkability (6MWT), increased IGF-1, no androgenic effects |
CD38 inhibition: amplifying the NAD+ effect
CD38 is the body's main NADase, and its activity increases dramatically with age and inflammation. Several natural molecules inhibit CD38 and can potentiate the effects of NAD+ precursors:
- Apigenin (parsley flavonoid, chamomile): non-competitive inhibitor of CD38, studied to potentiate the effect of NR/NMN
- Quercetin (senolytic, CD38/CD157 inhibitor)
- Luteolin : another CD38 inhibitor flavonoid
NAD+ and MOTS-c converge on common targets: AMPK (activated by both) and PGC-1α (activated downstream). In vitro studies show a potentiation of mitochondrial biogenesis when both pathways are stimulated simultaneously. Research protocols combining NAD+ and MOTS-c precursors are under development.
NAD+ and mitochondrial function
Mitochondria consume approximately 70% of cellular NAD+ for ATP production via the Krebs cycle and the electron transport chain. Restoring NAD+ levels improves:
- The activity of complexes I, II and III of the respiratory chain
- Mitochondrial dynamics (fusion/fission via SIRT3/DRP1)
- Selective mitophagy (elimination of dysfunctional mitochondria via PINK1/Parkin)
- Mitochondrial biogenesis (via SIRT1/PGC-1α)
NAD+ decline between 20 and 60 years
NAD+ dependent enzymes
NAD+ elevation with NR (300–1000 mg/day)
Molecular weight of NAD+
Safety and limitations
NAD+ precursors (NMN and NR) have a favorable safety profile in human studies published to date. No dose-limiting toxicity has been reported at doses up to 1000 mg/day of NR or 600 mg/day of NMN over 12-week periods. The most frequent adverse effects are mild and transient gastrointestinal disturbances.
Data on long-term effects (> 1 year) are still lacking. Whether the increase in blood NAD+ translates into a sufficient increase in the most important tissues (brain, heart muscle) remains a subject of debate. Studies on longevity in humans do not yet exist—all data come from animal models or intermediate biomarkers in humans.
Injectable NAD+ specifications
| Setting | Value |
|---|---|
| Full name | Nicotinamide adenine dinucleotide (oxidized form) |
| Formula | C₂₁H₂₇N₇O₁₄P₂ |
| Molecular weight | 663.43 Da |
| CAS Number | 53-84-9 |
| Presentation | Freeze-dried (powder) |
| Reconstitution solvent | Sterile water for injection (0.9% NaCl) |
| Freeze-dried stability | 24 months / −20°C or 2–8°C protected from light |
| Restored stability | 7 days / 2–8°C |
NAD+ and precursors available at MyPeptide
Lyophilized NAD+, NMN and NR in research grade. HPLC purity ≥99%, Janoshik COA, EU shipping 48–72h.
🧪 Buy NAD+ in Europe
Purity ≥99% HPLC · COA available per batch · Discreet shipping 48-72h
→ Buy NAD+ 100mg on MyPeptide.eu ·
Delivery to France, Belgium, Germany, Spain, Italy and all of Europe
Sources: Imai & Guarente 2014 — NAD+ and sirtuins · Yoshino et al. 2021 — NAD+ supplementation
📦 Buy NAD+ 100mg — Delivery to Europe
Available at MyPeptide.eu • Purity ≥99% HPLC • Janoshik COA • Shipping 48-72h
Scientific sources
- NAD+ in aging, metabolism, and neurodegeneration — Verdin E et al. (2015)
- NAD+ intermediates — the biology and therapeutic potential of NMN and NR — Yoshino J et al. (2018)
- Nicotinamide mononucleotide increases muscle insulin sensitivity — Yoshino M et al. (2021)
- Sirtuins and NAD+ in the development and treatment of metabolic disease — Kane AE et al. (2018)